Patents by Inventor Leonard G. Presta

Leonard G. Presta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240052009
    Abstract: Stabilized TCR constructs comprising a TCR alpha chain polypeptide having a variable alpha (V?) domain and a constant alpha (C?) domain and a TCR beta chain polypeptide having a variable beta (V?) domain and a constant beta (C?) domain. The TCR constructs are stabilized by the introduction into the C? domain and/or the C? domain of stabilizing mutations such as non-naturally occurring disulfide bonds between the C? domain and the C? domain (an interchain disulfide bond), non-naturally occurring intrachain disulfide bonds, point mutations, loop truncation mutations, and combinations thereof. TCR fusion proteins comprising one or more of the TCR constructs and a scaffold and/or other biologically active moiety are also described.
    Type: Application
    Filed: December 21, 2021
    Publication date: February 15, 2024
    Inventors: Eric ESCOBAR-CABRERA, Lee FREIBURGER, Daniel T. PATTON, Leonard G. PRESTA, Patrick FARBER, Charles Michael STEVENS
  • Patent number: 11873339
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: January 16, 2024
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: John Lippincott, Edward Thein Htun Van Der Horst, Sung Young Kim, Leonard G Presta, Jan-Willem Theunissen
  • Publication number: 20230312736
    Abstract: Provided herein are various embodiments relating to antibodies and fusion proteins and uses thereof. Some of the embodiments include antibodies that bind CCR8. Some of the embodiments include fusion proteins that bind CCR8. Such antibodies and fusion proteins can be used in methods to treat, for example, cancer.
    Type: Application
    Filed: March 10, 2023
    Publication date: October 5, 2023
    Inventors: Lara Lewis MCGRATH, Fabien DÉPIS, Changyun HU, Leonard G. PRESTA, Joshua Adam BUGGÉ
  • Publication number: 20230287110
    Abstract: Provided herein are anti-TREM2 antibodies and related methods of making and using anti-TREM2 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM2 antibody or antigen binding fragment thereof.
    Type: Application
    Filed: October 7, 2022
    Publication date: September 14, 2023
    Inventors: Michel Streuli, Venkataraman Sriram, Aritra Pal, Leonard G. Presta
  • Patent number: 11692038
    Abstract: Provided herein are various embodiments relating to antibodies and fusion proteins and uses thereof. Some of the embodiments include antibodies that bind CCR8. Some of the embodiments include fusion proteins that bind CCR8. Such antibodies and fusion proteins can be used in methods to treat, for example, cancer.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: July 4, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Lara Lewis McGrath, Fabien Dépis, Changyun Hu, Leonard G. Presta, Joshua Adam Buggé
  • Publication number: 20230203201
    Abstract: The present invention concerns binding molecules that comprise an IgM, IgA, IgG/IgM or IgG/IgA antibody with a J-chain modified to include an ADME-modulating moiety, and their uses.
    Type: Application
    Filed: November 11, 2022
    Publication date: June 29, 2023
    Inventors: Bruce A. KEYT, Leonard G. PRESTA, Ramesh BALIGA
  • Patent number: 11639389
    Abstract: The present invention provides binding molecules that include an IgM, IgA, IgG/IgM or IgG/IgA antibody with a modified J-chain that includes a binding moiety that antagonizes a T-cell inhibitory signaling pathway, and their uses.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: May 2, 2023
    Assignee: IGM Biosciences, Inc.
    Inventors: Bruce A. Keyt, Leonard G. Presta, Ramesh Baliga
  • Publication number: 20230096824
    Abstract: Antibody-drug conjugates (ADCs) are described, comprising anti-TM4SF1 antibodies, and antigen-binding fragments thereof. Methods of use of said ADCs are also described.
    Type: Application
    Filed: February 27, 2020
    Publication date: March 30, 2023
    Inventors: Paul A. JAMINET, Shou-Ching S. JAMINET, Edward H. HA, Leonard G. PRESTA, Manish S. HUDLIKAR
  • Patent number: 11572407
    Abstract: Provided herein are anti-MARCO antibodies. Provided are also methods of generating and using anti-MARCO antibodies.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: February 7, 2023
    Assignee: PIONYR IMMUNOTHERAPEUTICS, INC.
    Inventors: Nadine Jahchan, Michel Streuli, Xi Yang, Linda Liang, Venkataraman Sriram, Joshua Pollack, Kara Mojica, Vladislava Juric, Linnea Haeggblom, Leonard G. Presta, Sayantan Mitra
  • Patent number: 11542342
    Abstract: The present invention concerns binding molecules that comprise an IgM, IgA, IgG/IgM or IgG/IgA antibody with a J-chain modified to include an ADME-modulating moiety, and their uses.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: January 3, 2023
    Assignee: IGM Biosciences, Inc.
    Inventors: Bruce A. Keyt, Leonard G. Presta, Ramesh Baliga
  • Patent number: 11530247
    Abstract: This invention provides for a fusion protein between a single chain TNFR2 Selective Agonist protein (scTNFR2 Selective Agonist) and a dimerization domain, such as an IgGFc protein. The single chain TNFR2 Selective Agonist moiety provides a therapeutic activity by selectively activating the TNFR2 form of the TNF-? receptor, thus selectively stimulating Tregs and/or increasing myelin deposition.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: December 20, 2022
    Assignee: RELINIA, INC.
    Inventors: David C Foster, Lutz B Giebel, Leonard G Presta
  • Patent number: 11505602
    Abstract: Provided herein are anti-TREM2 antibodies and related methods of making and using anti-TREM2 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM2 antibody or antigen binding fragment thereof.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: November 22, 2022
    Assignee: PIONYR IMMUNOTHERAPEUTICS, INC.
    Inventors: Michel Streuli, Venkataraman Sriram, Aritra Pal, Leonard G. Presta
  • Publication number: 20220267461
    Abstract: Anti-TM4SF1 antibodies, and antigen-binding fragments thereof, are described that bind to an epitope on the ECL2 loop of human TM4SF1. Methods of use of said antibodies and fragments are also described, including for the inhibition of metastasis.
    Type: Application
    Filed: November 22, 2021
    Publication date: August 25, 2022
    Inventors: Paul A. Jaminet, Shou-Ching S. Jaminet, Harold F. Dvorak, Leonard G. Presta
  • Patent number: 11359025
    Abstract: Provided herein are antibodies specific for Interleukin-1 receptor accessory protein (IL1-RAP).
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: June 14, 2022
    Assignee: Cantargia AB
    Inventors: Ying Ping Jiang, Jagath R. Junutula, Leonard G. Presta
  • Publication number: 20220153860
    Abstract: Anti-TM4SF1 antibodies, and antigen-binding fragments thereof, are described that bind to an epitope on the ECL2 loop of human TM4SF1. Methods of use of said antibodies and fragments are also described, including for the inhibition of metastasis.
    Type: Application
    Filed: November 22, 2021
    Publication date: May 19, 2022
    Inventors: Paul A. Jaminet, Shou-Ching S. Jaminet, Harold F. Dvorak, Leonard G. Presta
  • Publication number: 20220153832
    Abstract: Provided herein are anti-MARCO antibodies. Provided are also methods of generating and using anti-MARCO antibodies.
    Type: Application
    Filed: November 18, 2021
    Publication date: May 19, 2022
    Inventors: Nadine Jahchan, Michel Streuli, Xi Yang, Linda Liang, Venkataraman Sriram, Joshua Pollack, Kara Mojica, Vladislava Juric, Linnea Haeggblom, Leonard G. Presta, Sayantan Mitra
  • Publication number: 20220002430
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Application
    Filed: April 20, 2021
    Publication date: January 6, 2022
    Applicant: Genentech, Inc.
    Inventors: Camellia W. ADAMS, Andrew C. CHAN, Craig W. CROWLEY, Henry B. LOWMAN, Gerald R. NAKAMURA, Leonard G. PRESTA
  • Patent number: 11208495
    Abstract: Anti-TM4SF1 antibodies, and antigen-binding fragments thereof, are described that bind to an epitope on the ECL2 loop of human TM4SF1. Methods of use of said antibodies and fragments are also described, including for the inhibition of metastasis.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: December 28, 2021
    Assignee: ANGIEX, INC.
    Inventors: Paul A. Jaminet, Shou-Ching S. Jaminet, Harold F. Dvorak, Leonard G. Presta
  • Publication number: 20210395388
    Abstract: Described herein are high affinity antigen binding constructs, e.g., antibodies, directed to the ECD2 domain of HER2. The antigen-binding constructs comprise at least one antigen-binding polypeptide construct that binds to ECD2 of HER2 (HER2 ECD2) with increased affinity compared to a wild-type 2C4 antibody. Such antigen-binding polypeptide constructs comprise one or more amino acid modifications in the framework region and/or CDRs compared to the amino acid sequence of a wild-type 2C4 antibody that increase affinity of the antigen-binding polypeptide construct for ECD2 by 2-fold or greater. The antigen-binding constructs can inhibit the growth of HER2-expressing breast cancer cells and gastric cancer cells. Antigen-binding constructs in biparatopic format are internalized in HER2-expressing cells.
    Type: Application
    Filed: May 3, 2021
    Publication date: December 23, 2021
    Inventors: Eric Escobar-Cabrera, Leonard G. Presta
  • Publication number: 20210371842
    Abstract: The present disclosure relates to antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. In one embodiment, the derivatives described herein lack or have reduced intrinsic coagulant activity.
    Type: Application
    Filed: June 18, 2019
    Publication date: December 2, 2021
    Inventors: Pamela B. Conley, Genmin Lu, Leonard G. Presta, John T. Curnutte